Design: Phase 3, randomised, double-blind, placebo-controlled trial
Population: 752 adults with type 2 diabetes and BMI 27 or more
Primary outcome: Percentage weight change and at least 5% weight loss at week 76
Effect: −8.2% (3.6 mg) and −9.8% (6.0 mg) vs −3.9% placebo

SYNCHRONIZE-2 randomised 752 adults with type 2 diabetes and a BMI of 27 or more (mean 36.5) to once-weekly subcutaneous survodutide 3.6 mg, 6.0 mg or placebo for 76 weeks. Survodutide acts on both glucagon and GLP-1 receptors; it is an investigational drug.

Mean weight change was −8.2% with 3.6 mg, −9.8% with 6.0 mg and −3.9% with placebo. At least 5% weight loss was reached by 57.6%, 64.5% and 35.1% respectively. HbA1c, from a baseline of 7.4%, fell by 0.9 and 0.8 percentage points against 0.2 with placebo. Gastrointestinal adverse events affected 72.8% and 77.7% against 38.6% with placebo.

Weight loss in type 2 diabetes is typically smaller than in obesity alone, and these results fit that pattern. There is no head-to-head comparison with semaglutide or tirzepatide here, and no outcome data, so the place of survodutide is not yet defined.

Expect smaller weight loss with incretin-based drugs in people with type 2 diabetes than without.
Survodutide is investigational and not licensed for use.
Gastrointestinal effects affected about three in four participants on the drug.
There is no head-to-head comparison with semaglutide or tirzepatide.
There are no cardiovascular or kidney outcome data yet.

Why it matters

The obesity-drug pipeline is widening beyond GLP-1 alone, but each new mechanism still has to show more than weight loss.

The statistics, in plain English

The difference from placebo is about 4.3 percentage points at 3.6 mg and 5.9 at 6.0 mg. The treatment-regimen estimand counts everyone as randomised, including those who stopped, so it reflects what happens in practice rather than in perfect adherence.